Obicetrapib Shows Promise for Heart Disease and Alzheimer's Prevention

Peter Attia explores obicetrapib, an investigational CETP inhibitor that has reignited interest in a drug class previously written off after spectacular failures. This matters because cardiovascular disease remains the leading cause of death, and effective treatments for high lipoprotein(a) levels are desperately needed.

Attia explains how CETP (cholesteryl ester transfer protein) moves cholesterol between lipoproteins, and why inhibiting it could be beneficial. He reviews the troubled history of earlier CETP inhibitors like torcetrapib, which actually increased cardiovascular events despite raising HDL cholesterol, teaching researchers that simply boosting HDL isn't protective.

The BROADWAY trial demonstrated obicetrapib's superior profile: significant reductions in LDL cholesterol, ApoB, and crucially, lipoprotein(a) - a genetic risk factor affecting millions. Unlike failed predecessors, obicetrapib appears to improve the lipid profile comprehensively rather than just manipulating HDL levels.

Perhaps most intriguingly, a substudy examined Alzheimer's biomarkers and found promising signals in APOE4 carriers, who face elevated dementia risk. The drug appeared to improve brain cholesterol metabolism, potentially offering neuroprotection alongside cardiovascular benefits.

Attia emphasizes cautious optimism while noting significant limitations. The Alzheimer's data comes from a small substudy, not a dedicated prevention trial. However, the dual potential for cardiovascular protection and cognitive preservation makes obicetrapib uniquely compelling, especially for APOE4 carriers who need both benefits most.